AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Harrow Health Inc. (HROW)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

30.16

-0.10 (-0.33%)

At close: Feb 20, 2025, 3:59 PM

30.10

-0.18%

After-hours: Feb 20, 2025, 04:01 PM EST

undefined% (undefined)

Bid	28
Market Cap	1.07B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.95
PE Ratio (ttm)	-31.74
Forward PE	n/a
Analyst	Buy

Ask	32.2
Volume	141,886
Avg. Volume (20D)	343,110
Open	30.23
Previous Close	30.26
Day's Range	29.61 - 30.59
52-Week Range	9.30 - 59.23
Beta	undefined

About HROW

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharma...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Sep 28, 2007

Employees 315

Stock Exchange NASDAQ

Ticker Symbol HROW

Website https://www.harrowinc.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for HROW stock is "Buy." The 12-month stock price forecast is $56, which is an increase of 85.71% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Harrow Health Inc. is scheduled to release its earnings on Mar 18, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

-17.26%

Harrow shares are trading lower after the company ... Unlock content with Pro Subscription

3 months ago

+3.79%

Harrow shares are trading lower after the company reported worse-than-expected Q3 sales results.

News

3 days ago · seekingalpha.com

I Am Loading Up Big Dividends For My Golden Years

Innovation, demand, and shortage of providers have kept healthcare inflation significantly higher than the CPI. Regardless of the political scene, the aging U.S. population and rising chronic illnesse...

3 weeks ago · businesswire.com

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through a strategi...

1 month ago · businesswire.com

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chi...

1 month ago · seekingalpha.com

Those Derisked Baby Bonds Of Harrow, Inc.

Harrow's 11.875% Senior Notes due 2027 are attractive baby bonds with a healthy leverage percentage of 13.8%, indicating strong creditworthiness and low debt. Harrow funds operations through product s...

2 months ago · seekingalpha.com

Harrow: The Triesence Relaunch

Harrow's relaunch of Triesence, a preservative-free corticosteroid, addresses a critical unmet need in ophthalmology, offering safer and more effective treatment options for eye care professionals. Tr...